Key points

  • BAKER BROS. ADVISORS LP, a director at Kodiak Sciences Inc. (KOD), reported buying $157.0 million of common stock. The purchases cover 1,941,755 shares in total.
  • The activity is spread across 82 separate SEC Form 4 filings, with the most recent transaction dated September 29th, 2026. That is an unusually long paper trail for a single reporting insider.
  • Reported purchase prices ran from $61.2104 to $89.8555. The stock last changed hands at $99.87, above the top of that range.
  • Kodiak Sciences carries a market capitalization of $6,276,775,424. The buyer is an institution, not an individual officer.

Kodiak Sciences Inc., a biological products company, has one insider doing nearly all of the reported buying. BAKER BROS. ADVISORS LP, which holds a director seat at the company, has reported purchases of 1,941,755 shares for a combined $157.0 million.

The buying is documented in 82 Form 4 filings, with the latest transaction dated September 29th, 2026. The reported prices on those purchases span $61.2104 to $89.8555.

What the filing shows

The filer is an entity rather than a person. BAKER BROS. ADVISORS LP is listed in the role of Director, a common arrangement when an investment firm holds a board seat and reports the positions of the funds it advises. Form 4 obligations attach to the firm in that case, which is one reason the filing count runs high.

The dollar figure, $157.0 million, is the total across all reported open market purchases in the window reviewed. The share count, 1,941,755, is the total number of shares acquired across those same filings. Neither number is a position size, and a Form 4 does not disclose what the filer already held before the first reported trade.

What the insiders did

Eighty-two filings is the detail worth sitting with. A single confirming purchase from an officer tends to arrive as one filing. A count in the dozens points to repeated buying on many separate dates, which is the pattern a fund produces when it is accumulating rather than making a one time statement.

The reported price range supports that reading. Purchases were logged as low as $61.2104 and as high as $89.8555. A spread that wide across one filer usually means the buying continued through different market conditions rather than clustering around a single event.

There is also a structural point. When an advisory firm sits on a board, its buying is governed by the same insider trading windows and blackout rules that apply to any director. The filings are a record of what the firm did inside those constraints. They say nothing about the firm's reasoning, and nothing in the Form 4 record addresses it.

Where the price sits

Kodiak Sciences last traded at $99.87. That is above $89.8555, the top of the reported purchase range, which means every reported purchase in this record was made below the most recent price.

That gap is a fact about timing, not a judgment about value. A buyer who accumulates steadily through a range will usually show some purchases above the eventual price and some below, and in this record all of them sit below. The low end, $61.2104, is a long way from where the shares trade now.

What that leaves

Kodiak Sciences is valued at $6,276,775,424. Against that, $157.0 million of reported director buying is meaningful in absolute terms without being a controlling stake on its own, and the filings do not disclose the firm's full ownership position.

The things worth weighing against the headline number are standard for biological products companies. Clinical outcomes, regulatory timelines and cash needs drive these businesses, and none of that appears on a Form 4. A director entity buying through a wide price range tells you what it did and when. It does not tell you what it expects.

One further caution: when a single filer accounts for essentially the entire reported buy side, the signal is concentrated. It reflects one decision maker's behavior rather than broad agreement among officers and directors.

Sources: SEC Form 4 filings retrieved via EDGAR and reviewed by InsiderBuying.com, covering reported transactions through September 29th, 2026.

Informational only, not investment advice.